Celadon Pharmaceuticals PLC Notice of Results and Investor Presentation (7427M)
September 18 2023 - 2:00AM
UK Regulatory
TIDMCEL
RNS Number : 7427M
Celadon Pharmaceuticals PLC
18 September 2023
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notice of Results and Investor Presentation
LONDON, 18 September 2023: Celadon Pharmaceuticals Plc (AIM:
CEL), a UK-based pharmaceutical company focused on the development,
production and sale of breakthrough cannabis-based medicines , will
announce its results for the six months ended 30 June 2023 on
Thursday 28 September 2023.
Analyst Briefing: 10.00am BST, Thursday 28 September 2023
Management will host a virtual analyst presentation followed by
a Q&A session at 10.00am BST on Thursday 28 September 2023.
Analysts wishing to join should register their interest by
contacting celadon@powerscourt-group.com .
Investor Presentation: 3.30pm BST, Thursday 28 September
2023
Management will be hosting a live presentation and Q&A
session via the online platform, Investor Meet Company, at 3.30pm
BST on Thursday 28 September 2023.
The presentation is open to analysts and all existing and
potential shareholders. Questions can be submitted pre-event via
the Investor Meet Company dashboard or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for free via:
https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
Investors who already follow Celadon on the Investor Meet
Company platform will automatically receive an invitation to the
event.
Enquiries:
Celadon Pharmaceuticals Plc
James Short, CEO Via Powerscourt
Arthur Wakeley, MD
Jonathan Turner, CFO
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Bobbie Hilliam / Max Hartley +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0)20 7250 1446
celadon@powerscourt-group.com
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and sale of
breakthrough cannabis-based medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and manufacturing and an analytical and R&D
laboratory. Celadon's Home Office licence allows for the commercial
supply of its GMP pharmaceutical cannabis product. The Group owns
an approved clinical trial using cannabis based medicinal products
to treat chronic pain in the UK. Celadon also has a minority
interest in early-stage biopharma Kingdom Therapeutics which is
developing a licensed cannabinoid medicine to treat children with
Autism Spectrum Disorder.
For further information please visit our website
www.celadonpharma.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORNKFBBPBKKACD
(END) Dow Jones Newswires
September 18, 2023 02:00 ET (06:00 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2024 to Jun 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2023 to Jun 2024